Phase 3 Study of Pembrolizumab in Esophageal and Esophagogastric Junction Cancers

Anne Li                                                                                               April 9th, 2017


For this randomized, phase 3 study (ClinicalTrials.gov Identifier: NCT02564263), patients who failed at least 1 line of standard therapy for advanced or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus, or Siewert type I adenocarcinoma of the esophagogastric junction, will receive single agent-agent pembrolizumab or investigator's choice of standard therapy.


See original article at: https://www.cancertherapyadvisor.com/gastrointestinal-cancers/clinical-trial-phase-3-pembrolizumab-esophageal-junction-cancer/article/649351/

Post a comment